Metabolic therapy with PEG-arginase induces a sustained complete remission in immunotherapy-resistant melanoma.

about

Metabolic therapy with PEG-arginase induces a sustained complete remission in immunotherapy-resistant melanoma.

Item

http://www.wikidata.org/entity/Q55260248

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Metabolic therapy with PEG-arg ...... unotherapy-resistant melanoma.

@en

Metabolic therapy with PEG-arg ...... unotherapy-resistant melanoma.

@nl

type

Item

label

Metabolic therapy with PEG-arg ...... unotherapy-resistant melanoma.

@en

Metabolic therapy with PEG-arg ...... unotherapy-resistant melanoma.

@nl

prefLabel

Metabolic therapy with PEG-arg ...... unotherapy-resistant melanoma.

@en

Metabolic therapy with PEG-arg ...... unotherapy-resistant melanoma.

@nl

P1476

Metabolic therapy with PEG-arg ...... munotherapy-resistant melanoma

@en

P2093

Alberto Bessudo

http://www.w3.org/2001/XMLSchema#string

Carmela De Santo

http://www.w3.org/2001/XMLSchema#string

Paul Cheng

http://www.w3.org/2001/XMLSchema#string

P2860

Invariant NKT cells modulate the suppressive activity of IL-10-secreting neutrophils differentiated with serum amyloid A

Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma.

Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target.

A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma.

Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival.

Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial.

Molecular basis and current strategies of therapeutic arginine depletion for cancer.

Recombinant human arginase inhibits the in vitro and in vivo proliferation of human melanoma by inducing cell cycle arrest and apoptosis.

Preliminary efficacy, safety, pharmacokinetics, pharmacodynamics and quality of life study of pegylated recombinant human arginase 1 in patients with advanced hepatocellular carcinoma.

Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.

P2888

s13045-018-0612-6

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.1186/S13045-018-0612-6

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Francis Jay Mussai

Sharon A Egan

Andrew Beggs

P577

2018-05-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1104089129

http://www.w3.org/2001/XMLSchema#string

P698

29776373

http://www.w3.org/2001/XMLSchema#string

P921

immunotherapy

P932

5960181

http://www.w3.org/2001/XMLSchema#string